证券代码：688314 证券简称：康拓医疗 公告编号：2025-004 西安康拓医疗技术股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 西安康拓医疗技术股份有限公司(以下简称"公司")第二届董事会第十五 次会议于2025年3月26日在公司会议室以现场及通讯表决的方式召开，会议通知 已于2025年3月14日通过邮件的方式送达全体董事。本次会议由董事长胡立人先 生主持，会议应出席董事9人，实际出席董事9人，部分监事、高级管理人员列 席。会议召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 《上海证券交易所科创板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《西安康拓医疗技术股份有限公司章程》（以下简称"《公司章 程》"）的规定，会议召开合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司2024年年度报告及摘要的议案》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票，回避票 0 票。 公司 2024 年年度报告的 ...

本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 证券代码：688314 证券简称：康拓医疗 告编号：2025-006 西安康拓医疗技术股份有限公司 关于 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例，每股转增比例：每 10 股派发现金红利 1.8 元（含 税）。 公司拟向全体股东每 10 股派发现金红利 1.8 元（含税）。截至 2024 年 12 月 31 日，公司总股本 81,239,172 股，以此计算合计拟派发现金红利 14,623,050.96 元（含税）。如在本公告披露之日起至实施权益分派股权登记日 期间，因可转债转股/回购股份/股权激励授予股份回购注销/重大资产重组股份 回购注销等致使公司总股本发生变动的，公司拟维持分配总额不变，相应调整 每股分配比例。如后续总股本发生变化，将另行公告具体调整情况。本次利润 分配方案尚需提交公司 2024 年年度股东大会审议。 公司于 2024 年 11 月 19 日 ...

Financial Performance - The company's operating revenue for 2024 reached ¥321,945,239.35, representing a year-on-year increase of 17.06% compared to ¥275,025,921.27 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥88,399,138.29, up 17.07% from ¥75,510,975.16 in 2023[18]. - The net cash flow from operating activities increased by 64.57% to ¥140,254,554.88 in 2024, compared to ¥85,224,591.84 in 2023[18]. - The company's total assets as of the end of 2024 were ¥747,222,862.91, a 10.57% increase from ¥675,787,403.12 at the end of 2023[19]. - The net assets attributable to shareholders increased by 8.24% to ¥635,577,490.21 at the end of 2024, compared to ¥587,184,063.37 at the end of 2023[19]. - Basic earnings per share for 2024 were ¥1.09, reflecting a 17.2% increase from ¥0.93 in 2023[20]. - The company reported a significant increase in other income by 153.69% to ¥13,329,126.18, mainly from subsidies for innovative medical devices[88]. - The gross margin for the medical device manufacturing sector was 80.23%, a decrease of 1.54 percentage points year-on-year[90]. - Domestic revenue accounted for 92.33% of total revenue, with a growth of 18.47% to ¥287,798,645.58[91]. - The company reported a net profit of 74.86 million yuan after deducting non-recurring gains and losses, reflecting a 9.52% year-on-year growth[29]. Research and Development - Research and development expenses accounted for 9.19% of operating revenue in 2024, up from 6.41% in 2023, indicating a focus on innovation[20]. - The company achieved a total R&D investment of ¥29,575,848.07, representing a 67.69% increase compared to the previous year[65]. - The proportion of R&D investment to operating income increased by 2.78 percentage points to 9.19%[65]. - The company obtained 4 new invention patents during the reporting period, focusing on PEEK bone plate technology and neurosurgery fixation techniques[63]. - The company has a cumulative total of 20 invention patent applications, with 14 granted[63]. - The company has successfully developed a unique micro-sphere production process that enhances the long-term efficacy of injectable fillers[70]. - The company has established multiple R&D platforms, including a 3D printing technology platform, to drive innovation and product development[177]. - The company emphasizes clinical demand-driven R&D, focusing on upgrading existing products and developing new technologies to address clinical pain points[54]. Corporate Governance - The company has a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[3]. - The company does not have any special arrangements for corporate governance[5]. - The company has improved its governance structure, optimizing its dividend policy and enhancing the role of independent directors to protect minority shareholders' rights[131]. - The company has established a specialized meeting mechanism for independent directors to strengthen their supervisory functions[131]. - The company has independent directors serving in various capacities, including positions at Guangdong Jinko Electronics Co., Ltd. and Xi'an Tianli Metal Composite Materials Co., Ltd.[138]. - The company's board of directors and supervisory board have confirmed the remuneration for directors, supervisors, and senior management for the 2023 fiscal year and proposed the remuneration plan for 2024[140]. - The company has established a comprehensive internal control system, which was independently audited and received a standard unqualified opinion for the 2024 internal control audit report[163]. Market Expansion and Product Development - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[18]. - The company has expanded its international business, covering over 30 countries, and is localizing PEEK bone plate production in the U.S. to enhance operational efficiency[37]. - The company is actively seeking partnerships with international leaders to introduce scarce bio-absorbable materials for craniofacial applications[33]. - The company is committed to enhancing the market influence of its craniofacial repair products through diversified promotion strategies, including online and offline marketing[128]. - The company aims to enhance its market share in the domestic neurosurgery segment while actively expanding its international business[125]. - By 2025, the company plans to increase the market penetration of PEEK material products and promote innovative products like the 4D bioactive plate and full PEEK cranial repair solutions[126]. Environmental and Social Responsibility - The company is committed to ESG principles, integrating sustainable development strategies into daily operations[165]. - The company donated a total of RMB 6 million for charity and poverty alleviation efforts during the reporting period[180]. - The company provided RMB 5 million in poverty alleviation donations to the local government, demonstrating its commitment to social responsibility[181]. - The company has implemented a waste management system for both general and hazardous waste, ensuring proper classification and disposal[173]. - The company emphasizes environmental protection and has established an emergency response mechanism for environmental pollution incidents[174]. Risks and Challenges - The company reported no significant risks affecting its operations during the reporting period[5]. - The company faces risks related to new product development and registration failures, which could adversely affect its long-term core competitiveness[78]. - The company is exposed to risks from centralized procurement policies, which may lead to price declines and impact profitability[80]. Employee Management and Development - The company has a structured training program aimed at enhancing employee skills and promoting career development[152][153]. - The number of R&D personnel increased to 53, representing 17.04% of the total workforce, up from 46 and 16.67% in the previous period[72]. - The average salary of R&D personnel is RMB 20.37 million, reflecting a slight increase from RMB 20.03 million in the previous period[72]. - The company has implemented a "key position personnel capability training plan" to support the growth of critical staff[129]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of 1.8 RMB per 10 shares, totaling approximately 14,623,050.96 RMB (including tax) based on a total share capital of 81,239,172 shares[4]. - The company has established a clear cash dividend policy to protect the rights of minority shareholders[155]. - The total cash dividend planned for 2024, including the first three quarters and the annual distribution, is RMB 29,246,101.92, representing 33.08% of the net profit attributable to shareholders[158]. - The cumulative cash dividend amount over the last three fiscal years (including tax) was CNY 85,417,186.56, representing a cash dividend ratio of 108.46% of the average annual net profit[159].

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 胡立人 | 3954.58 | 48.68 | 不变 | | 朱海龙 | 768.60 | 9.46 | 不变 | | 西安合赢企业管理咨询合伙企业(有限合伙) | 380.80 | 4.69 | 不变 | | 兴业银行股份有限公司-富国兴远优选12个月持有期混合 型证券投资基金 | 161.44 | 1.99 | 新进 | | 胡立功 | 130.76 | 1.61 | 不变 | | 中国工商银行股份有限公司-富国文体健康股票型证券投 资基金 | 107.85 | 1.33 | 新进 | | 王鹤 | 84.50 | 1.04 | 不变 | | 赵若愚 | 82.60 | 1.02 | 不变 | | 刘雯蕾 | 69.26 | 0.85 | 11.88 | | 吴栋 | 62.60 | 0.77 | 不变 | | 较上个报告期退出前十大股东有 | | | | | 上海弘翕投资发展中心(有限合伙) | 176.12 | 2 ...

Investment Rating - The investment rating for 康拓医疗 (688314.SH) is "Buy" (maintained) [1] Core Views - The company is expected to achieve steady revenue and profit growth in 2024, with a projected revenue of 322 million yuan, representing a year-over-year increase of 17.06%. The net profit attributable to the parent company is expected to be 89 million yuan, up 17.30% year-over-year [4][6] - The penetration rate of PEEK materials in the neurosurgery segment is anticipated to continue increasing, driven by the implementation of inter-provincial alliances for neurosurgery procurement in Henan province [4][6] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 89 million, 115 million, and 150 million yuan respectively, with corresponding EPS of 1.09, 1.42, and 1.85 yuan [4][6] Financial Summary - Revenue for 2024 is projected at 322 million yuan, with a year-over-year growth of 17.0%. The net profit for the same year is expected to be 89 million yuan, reflecting a growth of 17.3% [6][12] - The gross margin is projected to be 79.7% in 2024, with a net margin of 27.5% [6][12] - The P/E ratios for 2024, 2025, and 2026 are expected to be 30.7, 23.7, and 18.1 respectively [6][12] Product and Market Insights - PEEK neurosurgery products remain the main growth driver, with significant revenue growth expected from PEEK chest fixation devices [4] - The company has a comprehensive product line for cranial repair and fixation surgeries, with PEEK materials showing substantial growth potential in market penetration [4][6] - The company is expanding its overseas operations, including local production of PEEK plates in the U.S. to enhance market responsiveness and operational efficiency [4][6]

医药生物/医疗器械 康拓医疗（688314.SH） 2024 年收入利润稳健增长，PEEK 渗透率持续提升 2025 年 02 月 28 日 投资评级：买入（维持） 数据来源：聚源 -40% -20% 0% 20% 40% 60% 2024-02 2024-06 2024-10 康拓医疗 沪深300 | 日期 | 2025/2/27 | | --- | --- | | 当前股价(元) | 33.51 | | 一年最高最低(元) | 35.00/17.15 | | 总市值(亿元) | 27.22 | | 流通市值(亿元) | 27.22 | | 总股本(亿股) | 0.81 | | 流通股本(亿股) | 0.81 | | 近 3 个月换手率(%) | 52.34 | 相关研究报告 股价走势图 《2024H1 收入利润超预期，PEEK 骨 板渗透率提升中—公司信息更新报 告》-2024.8.14 《2023 年收入再创新高，PEEK 产品 成长力依旧可期—公司信息更新报 告》-2024.4.19 余汝意（分析师） 司乐致（分析师） 证书编号：S0790523070002 silezhi@kysec.cn 证书编号 ...

Financial Performance - In 2024, the company achieved total operating revenue of RMB 32,194.52 million, an increase of 17.06% compared to the previous year[6] - The net profit attributable to the parent company was RMB 8,857.08 million, reflecting a growth of 17.30% year-on-year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 7,503.25 million, up by 9.77% from the previous year[6] - Earnings per share rose to RMB 1.09, an increase of 17.20% from RMB 0.93 in the previous year[4] - The weighted average return on net assets improved to 14.57%, an increase of 1.11 percentage points from the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 74,706.60 million, a growth of 10.55% from the beginning of the period[6] - The equity attributable to the parent company increased to RMB 63,575.27 million, representing an 8.27% increase compared to the beginning of the period[6] Revenue Growth - The revenue from PEEK material neurosurgical products reached RMB 20,595.87 million, marking a 23.00% increase year-on-year[6] - The company accelerated the admission of neurosurgical products and expanded coverage in lower-tier markets, contributing to the net profit growth[7] Audit and Reporting - The company emphasizes that the financial data is preliminary and subject to final audit in the annual report[8]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-002 西安康拓医疗技术股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 1 朱海龙先生拟通过集中竞价和大宗交易方式减持其持有的公司股份合计不 超过 300,000 股，即不超过公司股份总数的 0.37%。本次减持自本减持计划公告 之日起 15 个交易日后的 3 个月内实施； 吴栋先生拟通过集中竞价和大宗交易方式减持其持有的公司股份合计不超 过 150,000 股，即不超过公司股份总数的 0.18%。本次减持自本减持计划公告之 日起 15 个交易日后的 3 个月内实施； 胡立功先生拟通过集中竞价和大宗交易方式减持其持有的公司股份合计不 超过 200,000 股，即不超过公司股份总数的 0.25%。本次减持自本减持计划公告 之日起 15 个交易日后的 3 个月内实施。 股东持股的基本情况 截至本公告披露日，西安康拓医疗技术股份有限公司（以下简称"公司"） 员工持股平台西安合赢企业管理咨询合伙企业（有限 ...

| 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/12/3 | 2024/12/4 | 2024/12/4 | 一、 通过分配方案的股东大会届次和日期 证券代码：688314 证券简称：康拓医疗 公告编号：2024-033 西安康拓医疗技术股份有限公司 2024 年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利 0.18 元 相关日期 本次利润分配方案经公司 2024 年 11 月 19 日的 2024 年第一次临时股东大会 审议通过。 二、 分配方案 1. 发放年度：2024 年前三季度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 81,239,172 股为基数，每股派发现 是否涉及差异化分红送转：否 每股分配比例 金红利 0.18 元 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2024-032 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安康拓医疗技术股份有限公司（以下简称"公司"）于近日取得国家药品 监督管理局颁发的第三类《医疗器械注册证》，具体情况如下： | 注册人名称 | 西安康拓医疗技术股份有限公司 | | | | | --- | --- | --- | --- | --- | | 产品名称 | 牙种植体及附件 | | | | | 适用范围/预期用途 | 通过外科手术方式将产品植入人体缺牙部位的上下颌 牙槽骨内，用于为义齿等修复体提供固定或支撑，以恢 | | | | | | 复患者的咀嚼功能。 | | | | | 注册证编号 | 国械注准 20243172292 | | | | | 类别管理 | 第三类 | | | | | 有效期至 | 月 日 2029 | 年 | 11 | 20 | 一、医疗器械注册证具体情况 本次获批的牙种植体及附件由种植体、覆盖螺丝组成，该产品为公司研发的 "高端骨结合种植体及附件产品开发"项目中的部分产 ...